Navigation Links
Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease
Date:12/12/2007

Data Suggest Continued Improvement in Motor Function at 24 Months

SAN DIEGO, Dec. 12 /PRNewswire/ -- Ceregene, Inc. today presented long-term follow-up data from a Phase 1 clinical trial of CERE-120 in 12 patients with advanced Parkinson's disease. CERE-120 uses gene therapy to deliver the neural growth factor neurturin to the major area of neurodegeneration that occurs in the brains of Parkinson's disease patients. Long-term follow up assessments at 18 and 24 months post treatment, suggest a sustained reduction in Parkinson's symptoms. It was previously reported that an average of 36 percent (p<0.001) reduction in Parkinson's symptoms was seen 12 months after CERE-120 administration. Of the 12 subjects treated, nine had shown a clinically meaningful reduction in symptoms at 12 months, and the mean improvement of these 'responders' at 12 months was 46 percent. Today it was reported that the eight evaluable responders exhibited a persistent mean improvement in symptoms of 52 percent at their longest time of follow-up (24 months for low-dose cohort and 18 months for high-dose cohort). More specifically, there was a statistically significant improvement in the primary endpoint compared to baseline (p<0.001) defined as the reduction in Parkinson's symptoms as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) motor "off" score ("motor off" meaning patients were off Parkinson's medication at evaluation time). CERE-120 continues to appear safe and well-tolerated, with no treatment-related or surgically-related serious adverse events reported for any of these patients. These data were presented today at the World Congress of Parkinson's Disease by Raymond T. Bartus, Ph.D., Ceregene's executive vice president of clinical and preclinical R&D and chief operating officer.

The Phase 1 trial was an open-label study conducted in 12 patients with advanced Parkinson's disease at two clinical trial sites -- University of California, San Francisco
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)...  Span-America Medical Systems, Inc. (NASDAQ:  SPAN) announced ... second quarter results on Thursday, April 30, after the ... will conduct a conference call at 10:00 a.m. ... financial and operating results for the second quarter ended ... conference call will be available online at ...
(Date:4/24/2015)... 24, 2015 Research and Markets ... addition of the "Lab Accessories Market ... Reservoir/Valve/Tubing/Wash Station) & End User (OEM/Biotechnology & ... to 2020" report to their offering. ... is expected to reach $504.7 million by ...
(Date:4/24/2015)... 24, 2015 The National Institute of ... National Institutes of Health [NIH])  provided grants totaling ... for the development of diagnostic tests for antibiotic-resistant ... at U.S. health facilities , the NIAID and ... multiplexed and effective tests using alternative methods to ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Kalorama: NIAID Rewards HAI Innovators with Grants 2Kalorama: NIAID Rewards HAI Innovators with Grants 3Kalorama: NIAID Rewards HAI Innovators with Grants 4
... Reportlinker.com announces that a new market ... , Reportlinker Adds Global Medical ... Sales Strategies and the Impact of Recession ... , Summary , "Global ...
... Corp. (TSX, FSE: HBP / OTCQX: HXBPF) today announced ... L-DOS47 product development programs following pre-investigational new drug ("pre-IND") ... , Helix requested the pre-IND meetings in order to ... filings with the FDA. The meeting on Topical Interferon ...
Cached Medicine Technology:Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 2Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 3Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 4Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 5Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 6Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 7Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 8Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 9Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 10Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 11Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 12Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 13Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery 14Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 2Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 3Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 4Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 5Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 6Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 7Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA 8
(Date:4/26/2015)... 26, 2015 With the FCPX LUT B&W ... editors can quickly and easily add desaturated color grades ... a mathematical formula for modifying an image. The LUT changes ... table. This pack comes with 60 black and white CUBE ... contemporary black and white films. With the FCPX LUT ...
(Date:4/26/2015)... In an article published last month in ... biomechanics occurring during the use of handheld electronic devices such ... that use of a tablet increases mechanical demand on neck ... more than when the neck is in a neutral position. ... pointing out the potential hazards of overuse of mobile technology ...
(Date:4/25/2015)... Diversified Communications has announced the launch ... Integrative Healthcare Symposium Canada, as it’s titled, will ... Sheraton Parkway Toronto North in Ontario. , The ... most anticipated events of the year and will ... event aims to gather multi-disciplined practitioners from all ...
(Date:4/25/2015)... New York, New York (PRWEB) April 25, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) established for vaginal mesh lawsuits filed ... in the U.S. District Court, Southern District of ... April 9th, a Scheduling Conference was convened that ... the Plaintiffs’ Master Long Form Complaint. The Order ...
(Date:4/25/2015)... Gardant Management Solutions will lead ... operations, and sales and marketing at the LeadingAge ... be held from April 29 through May 1 ... largest eldercare association in Illinois. The statewide association ... adults, including senior housing, assisted living and supportive ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios, a FCPX Effects Developer, Announced the Release of FCPX LUT B&W 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Integrative Healthcare Event launching in Canada 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Gardant Management Solutions Staff Shares Operational Expertise 2
... EAST LANSING, Mich. Curcumin, a compound found in ... of a protein involved in Parkinson,s disease, says a ... led by Basir Ahmad, an MSU postdoctoral researcher, demonstrated ... cause of clumping, or aggregation, which is the first ...
... March 15, 2012, the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) celebrated ... for all employees in the Technische Sammlungen Dresden ... HZDR,s outstanding scientific achievements of the last year ... Mller-Steinhagen, Rector of the TU Dresden [Dresden University ...
... (LPS) has been found to elevate amyloid beta (Aβ) ... in learning. "We have found that after ... LPS administration) mice showed significant elevation in Aβ levels ... biology at Texas Christian University in Fort Worth. ...
... in St. Louis have shown that a new drug makes ... of the white blood cells. Instead of attacking these cells ... marrow and into the bloodstream, where they are more vulnerable ... leukemia cells from the blood," says Geoffrey L. Uy, MD, ...
... off, one in a white judogi (the traditional judo uniform) ... and lock arms, in what looks like an awkward dance, ... the mat. Judo and mixed martial arts have become ... taken note. The two fighters were actually filmed as part ...
... (Philadelphia) Intervention by peer mentors has a statistically significant ... diabetes, according to a study by researchers at the Perelman ... Philadelphia VA Center for Health Equity Research and Promotion (CHERP). ... 20th issue of the Annals of Internal Medicine. ...
Cached Medicine News:Health News:Curcumin shows promise in attacking Parkinson's disease 2Health News:Dresden's Helmholtz Center celebrates anniversary and presents HZDR awards 2Health News:Dresden's Helmholtz Center celebrates anniversary and presents HZDR awards 3Health News:Drug makes leukemia more vulnerable to chemo 2Health News:Drug makes leukemia more vulnerable to chemo 3Health News:Scientists measure how energy is spent in martial arts 2Health News:Penn researchers find mentoring provides health benefits for African American veterans with diabetes 2Health News:Penn researchers find mentoring provides health benefits for African American veterans with diabetes 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: